These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Early appearance of osteonecrosis of the jaw after zoledronic acid in a patient with a long history of taking oral bisphosphonates.
    Author: Uña E.
    Journal: BMJ Case Rep; 2012 Mar 27; 2012():. PubMed ID: 22605820.
    Abstract:
    Osteonecrosis of the jaw (ONJ) is a serious side effect in patients receiving intravenous nitrogen-containing bisphosphonates (B). It has also been reported to occur due to oral administration of B. Most cases will appear after receiving B for more than 1 year. The authors report a case of a 67-year-old woman with osteoporosis who had received oral alendronate sodium for 2 years and stopped the treatment due to dyspepsia. 18 months later she was diagnosed with breast cancer and bone metastases. She started a treatment based on aromatase inhibitors and zoledronic acid (Z). She developed ONJ soon after the third administration. She was treated with antibiotics, anti-inflammatories and a chlorexidine colutory. She recovered 3 months later. ONJ secondary to Z may occur also earlier than it was thought in patients with a history of taking oral B.
    [Abstract] [Full Text] [Related] [New Search]